

**RETRACTION****Retraction: Safety and Efficacy of Biodegradable Patent Foramen Ovale Occluder in Patients with Migraine: A Clinical Trial**

Xingbang Li^{1,#}, Xuan Zheng^{2,#}, Bowen Jin¹, Yunyan Li¹, Yongyu Shao¹, Xiaoxian Deng¹, Dingyang Li¹, Shanshan Li¹, Hongmei Zhou¹, Jie Zhang³, Xianya Zhang⁴, Qunshan Shen¹ and Gangcheng Zhang^{2,*}

¹Congenital Heart Disease Center, Wuhan Asia Heart Hospital, Wuhan University of Science and Technology, Wuhan, 430022, China

²Structural Heart Disease Center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China

³Department of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

⁴Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

Published: 15 September 2023

The published article titled “Safety and Efficacy of Biodegradable Patent Foramen Ovale Occluder in Patients with Migraine: A Clinical Trial”, has been retracted from journal *Congenital Heart Disease*, Vol. 18, No. 3, 2023, pp. 373–385.

DOI: [10.32604/chd.2023.028979](https://doi.org/10.32604/chd.2023.028979)

URL: <https://www.techscience.com/chd/v18n3/53122/html>

The authors declare that due to the following reasons, they have to retract the published article from *Congenital Heart Disease*:

The retraction has been agreed upon due to the re-assessment of RLS at six months being missing, which would induce significant bias to current conclusions. The authors have made great efforts to recover those data. However, they have yet to be available currently. It would be impossible to add those data in a short time. Current conclusions might mislead the audience, which was not the original purpose of publishing our paper. After careful consideration, the authors require to withdraw their paper.

The Editor-in-Chief of CHD has reviewed and agreed to retract this article from *Congenital Heart Disease*.

